Cargando…
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
OBJECTIVE: To assess baseline characteristics and antithrombotic treatment (ATT) prescription patterns in patients enrolled in the third phase of the GLORIA-AF Registry Program, evaluate predictors of treatment prescription, and compare results with phase II. METHODS: GLORIA-AF is a large, global, p...
Autores principales: | Beier, Lea, Lu, Shihai, França, Lionel Riou, Marler, Sabrina, Lip, Gregory Y. H., Huisman, Menno V., Teutsch, Christine, Halperin, Jonathan L., Zint, Kristina, Diener, Hans-Christoph, Baker, Laurie, Ma, Chang-Sheng, Paquette, Miney, Bartels, Dorothee B., Dubner, Sergio J., Lyrer, Philippe, Senges, Jochen, Rothman, Kenneth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536607/ https://www.ncbi.nlm.nih.gov/pubmed/36201473 http://dx.doi.org/10.1371/journal.pone.0274237 |
Ejemplares similares
-
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
por: Mazurek, Michał, et al.
Publicado: (2017) -
Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
por: Kozieł, Monika, et al.
Publicado: (2020) -
Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020) -
Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
por: van der Wall, Sake J., et al.
Publicado: (2021) -
Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)